COMBINED CHEMOTHERAPY INCLUDING PROCARBAZINE (NATULAN) IN THE TREATMENT OF ANAPLASTIC OLIGODENDROGLIOMAS
https://doi.org/10.17650/2222-1468-2012-0-1-14-16
Abstract
Our investigation has demonstrated the high efficiency of combined chemotherapy (CT) including procarbazine + lomustine or procarbazine + lomustine + vincristine in patients with anaplastic oligodendrogliomas. Postoperative CT has been recently recommended for patients with deletion of chromosomes 1p and 19q, by taking into account the good prognosis of a therapeutic effect, better parameters of time till progression in this patient group, and a risk for cognitive impairments after brain radiotherapy.
About the Authors
D. R. Naskhletashvili
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
A. Kh. Bekyashev
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
V. B. Karakhan
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
V. A. Aleshin
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
R. G. Fu
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
D. M. Belov
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
E. G. Chmutin
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. Bauman G.S., Ino Y., Yeki K. et al. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendroglioma. Int J Radiat Oncol Biol Phys 2000;48:825–30.
2. Bello M.J., Leone P.E., Vaquero J., de Campos J.M., Kusac M.E., Sarasa J.I. et al. Allelic loss at 1p at 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer 1995;64:207–10.
3. Caincross J.G., Macdonald D.R. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 1988;23:360–4.
4. Ino Y., Betensky R.A., Ziatescu M.C., Sasaki H., Macdonald D.R. et al. Molekular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001;7:839.
5. Macdonald D.R., Gaspar L.E., Cairnocross J.G. Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol 1990;27:573–4.
6. Pilo de la Fuente B., Dalmau J., Rosenfeld M. Actualization del tratamiento de los gliomas. Neurologia 2007; 22(3):159–69.
7. Reifenberger J., Reifenberger G., Liu L., James C.D., Wechsler W., Collins V.P. Molecular genetic analysis of oligodendroglioma tumors shows preferential allelic deletion 19q and 1p. Am J Pathol 1994;145:1175–90.
8. Smith J.S., Perry A., Borell T.J. et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytoma, and mixed oligoastrocytomas. J Clin Oncol 2000;18:636–45.
9. Soffietti R. Chemotherapy of anaplastic oligodendroglial tumors. Expert Opin Pharmacother 2004;5:295–306.
10. Van den Bent M.J., Looijenga L.H., Langenberg K. et al. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 2003;97:1276–84.
11. Vesper J., Graf E., Wille C., Tilgner J., Trippel M., Nikkhah G. and Ostertag C.B. Retrospective analysis of treatment outcome in 315 patients with oligodendroglial brain tumors. BMC Neurol 2009 Jul 16;9:33; doi:10.1186/1471-2377-9-33.
Review
For citations:
Naskhletashvili D.R., Bekyashev A.Kh., Karakhan V.B., Aleshin V.A., Fu R.G., Belov D.M., Chmutin E.G. COMBINED CHEMOTHERAPY INCLUDING PROCARBAZINE (NATULAN) IN THE TREATMENT OF ANAPLASTIC OLIGODENDROGLIOMAS. Head and Neck Tumors (HNT). 2012;(1):14-16. (In Russ.) https://doi.org/10.17650/2222-1468-2012-0-1-14-16
Views:
1141
Email this article 